Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome

World News: . []

NEW YORK Dec 06 2018 GLOBE NEWSWIRE -- Ovid Therapeutics Inc NASDAQOVID a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases today announced plans to move ahead with a...

More news and information about Ovid Therapeutics Inc.

Published By:

Globe Newswire: 13:01 GMT Thursday 6th December 2018

Published: .

Search for other references to "ovid" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us